Why Evolent Health, Inc.’s (EVH) Stock Is Up 5.47%
As of Wednesday, October 07, Evolent Health, Inc.’s EVH share price has surged by 5.47%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Commentary & Analysis
Why Evolent Health, Inc.’s (EVH) Stock Is Down 5.21%
As of Tuesday, September 29, Evolent Health, Inc.’s EVH share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Michael Rose
Why Evolent Health, Inc.’s (EVH) Stock Is Down 5.67%
As of Tuesday, September 08, Evolent Health, Inc.’s EVH share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Is Evolent Health, Inc. (EVH) Overvalued?
We dive into why Evolent Health, Inc. (EVH) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Evolent Health, Inc.’s (EVH) Stock Is Up 5.49%
As of Wednesday, August 12, Evolent Health, Inc.’s EVH share price has surged by 5.49%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | EVH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $456.8 | $156.0 | 36% |
|
| Shares Out (Mil) | 112.5 | 42.5 | 64% |
|
| Institutional Ownership | 97.7% | 78.5% | 75% |
|
| Float (Mil) | 94.2 | 38.7 | 59% |
|
| Beta | 0.84 | 1.17 | 50% |
|
| Avg Daily Volume (000s) | 2,179 | 418 | 82% |
|
| Price Change (52-week) |
(49.8%) | 44.8% | 19% |
|
| Growth | EVH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.2% | 11.8% | 73% |
|
| Net Income (5yr) | (9.8%) | 2.7% | 29% |
|
| EPS (5yr) | (5.2%) | 15.5% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (62.6%) | (15.8%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | $0.060 | $0.200 | $0.404 | |
| Month Ago EPS | $0.060 | $0.200 | $0.391 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.054 | $0.197 | $0.385 | |
| Year/Year Chg | (123.8%) | (103.9%) | (110.8%) | |
| Financials | EVH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,097 | $202 | 61% |
|
| Net Income (TTM) (Mil) | ($505) | ($9) | 3% |
|
| EPS (TTM) | ($4.542) | ($1.000) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | $54 | ($1) | 47% |
|
| Net Cash Flow (TTM) (Mil) | ($37) | $3 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $969 | $18 | 66% |
|
| Enterprise Value (Q1) (Mil) | $1,272 | $160 | 44% |
|
| Valuation | EVH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.19 | 1.28 | 31% |
|
| P/E | na | 42.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.7 | na |
|
| Ratios | EVH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 17.2% | 60.9% | 17% |
|
| Net Margin | (24.1%) | (26.3%) | 15% |
|
| ROA | (22.8%) | (22.8%) | 19% |
|
| ROE | (79.0%) | (9.8%) | 11% |
|
| Liabilities to Assets | 80.6% | 33.3% | 75% |
|
| F-Score | 6 | 4 | 67% |
|
Evolent Health, Inc. did not pass any screens on 10/9/2026.
